Sulfamethizole Disease Interactions
There is 1 disease interaction with sulfamethizole.
Sulfonamides (applies to sulfamethizole) hematologic toxicity
Major Potential Hazard, Moderate plausibility. Applicable conditions: G-6-PD Deficiency
The use of sulfonamides has been associated with hematologic toxicity, including methemoglobinemia, sulfhemoglobinemia, leukopenia, granulocytopenia, eosinophilia, hemolytic anemia, aplastic anemia, purpura, clotting disorder, thrombocytopenia, hypofibrinogenemia, and hypoprothrombinemia. Acute dose-related hemolytic anemia may occur during the first week of therapy due to sensitization, while chronic hemolytic anemia may occur with prolonged use. Patients with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency should be observed closely for signs of hemolytic anemia. Therapy with sulfonamides should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression. Complete blood counts should be obtained regularly, especially during prolonged therapy (>2 weeks), and patients should be instructed to immediately report any signs or symptoms suggestive of blood dyscrasia such as fever, sore throat, local infection, bleeding, pallor, dizziness, or jaundice.
References
- Barak S, Shaked Y, Bar A, Samra Y (1989) "Drug-induced post-surgical hemorrhage resulting from trimethoprim-sulphamethoxazole." Int J Oral Maxillofac Surg, 18, p. 206-7
- Chan M, Beale D, Moorhead J (1980) "Acute megaloblastosis due to cotrimoxazole." Br J Clin Pract, 34, p. 87-8
- Damergis J, Stoker J, Abadie J (1983) "Methemoglobinemia after sulfamethoxazole and trimethoprim therapy." JAMA, 249, p. 590-1
- Finland M, Strauss E, Peterson O (1984) "Sulfadiazine." JAMA, 251, p. 1467-74
- Kuipers EJ, Vellenga E, de Wolf JT, Hazenberg BP (1992) "Sulfasalazine induced agranulocytosis treated with GM-CSF." J Rheumatol, 19, p. 621-2
- Youssef PP, Bertouch JV (1992) "Sulphasalazine induced aplastic anaemia." Aust N Z J Med, 22, p. 391-2
- Keisu M, Ekman E (1992) "Sulfasalazine associated agranulocytosis in sweden 1972-1989: clinical features, and estimation of its incidence." Eur J Clin Pharmacol, 43, p. 215-8
- "Product Information. Gantranol (sulfamethoxazole)." Roche Laboratories, Nutley, NJ.
- (2001) "Product Information. Gantrisin (sulfisoxazole)." Roche Laboratories
- (2001) "Product Information. Sulfadiazine (sulfadiazine)." Eon Labs Manufacturing Inc
- Peppercorn MA (1984) "Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development." Ann Intern Med, 101, p. 377-86
- Jacobson IM, Kelsey PB, Blyden GT, Demirjian ZN, Isselbacher KJ (1985) "Sulfasalazine-induced agranulocytosis." Am J Gastroenterol, 80, p. 118-21
- Wheelan KR, Cooper B, Stone MJ (1982) "Multiple haematologic abnormalities associated with sulfasalazine." Ann Intern Med, 97, p. 726-7
- Pena JM, Gonzalez-Garcia JJ, Garcia-Alegria J, Barbado FJ, Vazquez JJ (1985) "Thrombocytopenia and sulfasalazine." Ann Intern Med, 102, p. 277-8
- Davies GE, Palek J (1980) "Selective erythroid and magakaryocytic aplasia after sulfasalazine administration." Arch Intern Med, 140, p. 1122
- Guillemin F, Aussedat R, Guerci A, Lederlin P, Trechot P, Pourel J (1989) "Fatal agranulocytosis in sulfasalazine treated rheumatoid arthritis." J Rheumatol, 16, p. 1166-7
- Mitrane MP, Singh A, Seibold JR (1986) "Cholestasis and fatal agranulocytosis complicating sulfasalazine therapy: case report and review of the literature." J Rheumatol, 13, p. 969-72
- Mechanick JI (1985) "Coombs' positive hemolytic anemia following sulfasalazine therapy in ulcerative colitis: case reports, review, and discussion of pathogenesis." Mt Sinai J Med, 52, p. 667-70
- Betkowski AS, Lubin A (1993) "Sulfamethoxazole-related antiplatelet antibody." Blood, 82, p. 1683
- Gales BJ, Gales MA (1993) "Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis." Ann Pharmacother, 27, p. 1052-4
- (2001) "Product Information. Azulfidine (sulfasalazine)." Pharmacia and Upjohn
- Bates CM (1996) "HIV medicine: drug side effects and interactions." Postgrad Med J, 72, p. 30-6
- (2001) "Product Information. Zonegran (zonisamide)." Elan Pharmaceuticals
- Hopkinson ND, Garcia FS, Gumpel JM (1989) "Haematological side-effects pf sulphasalazine in inflammatory arthritis." Br J Rheumatol, 28, p. 414-7
- Logan EC, Williamson LM, Ryrie DR (1986) "Sulphasalazine associated pancytopenia may be caused by acute folate deficiency." Gut, 27, p. 868-72
Sulfamethizole drug interactions
There are 125 drug interactions with sulfamethizole.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.